Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 98

Results For "EU"

4805 News Found

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia
News | August 08, 2025

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men


WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies
Biotech | August 08, 2025

WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies

The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines


Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
News | August 08, 2025

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore


Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
News | August 06, 2025

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter


AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
Drug Approval | August 06, 2025

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial


Athena Diagnostics enhances Ataxia testing with long-read gene sequencing
Diagnostic Center | August 06, 2025

Athena Diagnostics enhances Ataxia testing with long-read gene sequencing

Athena is also exploring the use of this technology for expanded carrier screening


Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
News | August 06, 2025

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs


Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
News | August 06, 2025

Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint


Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers
News | August 03, 2025

Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product